Pfizer Mega-Merger Pursuit Overshadows Consumer Slump
This article was originally published in The Tan Sheet
The firm’s overall performance – revenues down 9% to $11.4 billion and net income down 15% to $2.3 billion – underscores how much Pfizer needs to acquire AstraZeneca after disclosing its pursuit of the U.K. pharma.
You may also be interested in...
“When COVID-19 hit, we really decided to accelerate plans,” says BlueWillow CEO Dave Peralta. NanoBio Protect contains OTC monograph ingredient benzalkonium chloride in a proprietary nanotechnology, alcohol-free formulation to help reduce germs on skin inside and around the nose that could cause infections.
Trade group also compiled website with information and resources to help members "stay up to date and take any necessary steps to mitigate the risks associated with COVID-19." Its members also got a chance to describe potential supply chain disruptions in survey for USDA.
FDA and FTC's latest warning letters include the first firm marketing CBD products linked with bogus COVID-19 claims. Latest warnings also mark the first the agencies submitted based completely or nearly entirely on regulatory violations found in businesses social media postings.